Eos Management L.P. Lowers Position in Danaher Corporation $DHR

Eos Management L.P. reduced its position in shares of Danaher Corporation (NYSE:DHR) by 37.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,534 shares of the conglomerate’s stock after selling 15,033 shares during the period. Danaher makes up approximately 2.2% of Eos Management L.P.’s portfolio, making the stock its 15th largest position. Eos Management L.P.’s holdings in Danaher were worth $5,044,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the period. Sierra Ocean LLC boosted its position in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in shares of Danaher during the 1st quarter worth $31,000. Red Tortoise LLC increased its holdings in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares in the last quarter. Finally, Costello Asset Management INC acquired a new stake in shares of Danaher in the first quarter valued at about $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.20% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $209.14 on Monday. Danaher Corporation has a one year low of $171.00 and a one year high of $275.51. The stock has a market cap of $149.76 billion, a PE ratio of 44.50, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77. The business’s fifty day moving average price is $201.60 and its two-hundred day moving average price is $197.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business’s revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is presently 27.23%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DHR shares. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Evercore ISI boosted their target price on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $245.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.